A self-controlled case series to evaluate the effects of clinical trial eligibility criteria on biologic-associated reductions in severe asthma exacerbations: an analysis of the CHRONICLE study.

In 30 seconds

This study examined whether eligibility criteria used in biologic trials identify adults with severe asthma who are more likely to benefit. It combined a meta-analysis of six randomised trials with a self-controlled case-series analysis of CHRONICLE, a multicentre prospective US cohort. Biologics were associated with lower severe exacerbation rates in both analyses: rate ratio 0.53 (95% CI 0.47-0.60) in the trial meta-analysis and IRR 0.43 (95% CI 0.39-0.48) among 480 cohort participants. Treatment response varied by smoking, exacerbation history, exhaled nitric oxide, and blood eosinophil criteria.

Key findings

• In the CHRONICLE self-controlled analysis, biologic-exposed periods had fewer severe exacerbations than unexposed periods (IRR 0.43, 95% CI 0.39-0.48).
• The meta-analysis of six RCTs found a pooled exacerbation rate ratio of 0.53 (95% CI 0.47-0.60) with biologics.
• Effect modification was observed for smoking history, exacerbation history, exhaled nitric oxide fraction, and blood eosinophil count.
• COPD, bronchiectasis, and forced expiratory volume in 1 s criteria showed no significant response differences, despite spirometry criteria excluding the most cohort participants.

Why it matters

Trial eligibility rules shape both the populations studied and the applicability of results to routine care. These findings suggest that smoking history, prior exacerbations, and type 2 biomarkers may help identify populations with greater biologic-associated benefit, while some spirometry-based exclusions may narrow generalisability without clearly distinguishing treatment response.

What to keep in mind

The real-world analysis was nonrandomised and self-controlled, so it cannot establish the causal effect of biologics as securely as a randomised trial.